On May 29, the official website of the National Medical Products Administration (NMPA) showed that Naldemedine Tosilate tablets was approved for marketing for the treatment of opioid-induced constipation (OIC) in adults.

On May 28, GlaxoSmithKline (LSE/NYSE: GSK) announced positive pivotal data for bepirovirsen, an antisense oligonucleotide (ASO) drug for the treatment of chronic hepatitis B (CHB). The results of two Phase III clinical trials, B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820), were simultaneously published in the New England Journal of Medicine and presented at the European Association for the Study of the Liver (EASL) Congress. On May 11, Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), entered into an exclusive strategic cooperation with GlaxoSmithKline (GSK) to accelerate the marketing process of bepirovirsen in China.

Recently, S&P Global, an internationally authoritative sustainability assessment agency, held the launch ceremony for "The Sustainability Yearbook" (China Edition) 2026 in Shanghai.

Recently, the preclinical and Phase I clinical results of TQB2102 (a HER2 bispecific-bispecific ADC), a first-in-class (FIC) new drug independently developed by Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), for the treatment of advanced solid tumors, were published online in Annals of Oncology (impact factor 65.4), the flagship journal of the European Society for Medical Oncology (ESMO). This study, led by the team of Academician Xu Ruihua and Professor Wang Shusen from Sun Yat-sen University Cancer Center, for the first time systematically released the efficacy and safety data of TQB2102 from human clinical studies, and simultaneously disclosed its preclinical research results, confirming the differentiated characteristics of TQB2102 as a bispecific HER2 ADC.

In the field of advanced gastric cancer, CLDN18.2 is the second hot target after HER2 to have its druggability validated, with approximately 38.4% of gastric cancer patients showing high expression of CLDN18.2. On May 22, the CLDN18.2 ADC, Tecotabart Vedotin Monoclonal Antibody for Injection (LM-302), independently developed by LaNova Medicines, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), and submitted by Shanghai Chia Tai Tianqing, was officially included in the priority review and approval process.

On May 22, Chia Tai Tianqing Pharmaceutical Group, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), donated 100 million yuan to the China Science and Technology Development Foundation. This move actively implements the national "15th Five-Year Plan" strategic layout, helps build the biopharmaceutical industry into a national emerging pillar industry, and empowers the nation's high-level scientific and technological self-reliance with concrete actions.

On May 21, Sino Biopharmaceutical Limited (SBP Group, 1177.HK) and Boehringer Ingelheim jointly announced that Hernexeos® (generic name in Chinese: zongertinib tablets, generic name in English: zongertinib), which they are co-promoting in mainland China, has been approved by the China National Medical Products Administration (NMPA).

Recently, the world-renowned business magazine Fortune released the "2026 China Environmental, Social, and Governance (ESG) Impact List".

Recently, for Kylo-11 (LPA-siRNA), independently developed by Hygieia Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), the enrollment of all subjects in the China region for a Phase II clinical trial has been successfully completed.

On May 14, the 6th CICC Healthcare Industry Summit 2026 was held in Shanghai. Theresa Tse, Chairwoman of the Board of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), attended and delivered a speech, providing a clear answer for achieving a global breakthrough through a differentiated M&A strategy for local Chinese pharmaceutical companies, combined with a leading advantage across the entire value chain.